SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Catalent eyes emerging market expansion of end-to-end development service model

By Natalie Morrison , 04-Apr-2012
Last updated the 04-Apr-2012 at 13:42 GMT

Loading...

Catalent wants to build on its European expansions by replicating the end-to-end drug development services model in emerging markets. 

Speaking to Outsourcing-Pharma at DIA Euromeeting in Denmark, VP of global regulatory consulting Carolyn Finkle said recent expansions in the UK and Germany are intended to copy its “one-stop-shop” services in the US for European customers.

But Europe is not the only target for Catalent – the firm has set its sights on providing an end-to-end drug development service globally, with future focus on emerging markets, said Finkle. Catalent spoke last year of its interest in expanding in China and India through acquisitions.

“We are also looking to establish bases in emerging countries where clients are looking at bringing their products,” Finkle said. New services will accompany the geographic expansion to make Catalent "a solutions provider rather than a transactional vendor,” she said.

Of the latest expansion in Swindon she said: “This will provide a host of analytical services for companies developing products in Europe, who want to do method development analytical testing, and stability testing.”

Regulation domination

The new capabilities coincide with the growth of the company’s regulatory services, including a recent expansion of provisions in the US.

“We basically can help from very early stage development, to later down facilitating some of the full applications, like interacting with the marketing authorisation authority in Europe or the NDA (new drug application) in the US”.

Related products

Kemwell CEO says environmental efforts are worth the cost

Kemwell CEO says environmental efforts are worth the cost

Kemwell CEO Agneta Bergvall says drugmakers' efforts to make pharmaceutical manufacturing green are worth...

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Will Downie

Senior VP Global Vusiness Development & Marketing, Catalent

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

Quincy Mattingly

Regional Manager, AlpVision

Cobra Biologics talks recent fill finish acquisition and future growth plans

Cobra Biologics talks recent fill finish acquisition and future growth plans

Philip Ridley-smith

Business Development & Marketing Manager, Cobra Biologics

Catalent says sharing with industry will not dull competetive edge

Catalent says sharing with industry will not dull competetive edge

Kurt Nielsen and Cornell Stamoran

Various, Catalent

Bend Research hunting new partnerships to boost bioavailability offering

Bend Research hunting new partnerships to boost bioavailability offering

David Lyon and Karen Coppens

Various, Bend Research and Dow

Changes to EU clinical trial laws will mean fairer playing field, says Clinipace

Changes to EU clinical trial laws will mean fairer playing field, says Clinipace

Andrea Schiefer

VP of European clinical operations and executive director of pharmacovigilance,...

Home visits = regulatory thumbs up? ResearchNurses.co thinks so

Home visits = regulatory thumbs up? ResearchNurses.co thinks so

Sue Mackay

Research nursing team manager, ResearchNurses.co

Consolidation prevalent in industry, says third largest CMO

Consolidation prevalent in industry, says third largest CMO

Brad Carlson

VP Marketing 7 Sales, Aenova

Catalent commits to ADCs by upping its stake in Redwood

Catalent commits to ADCs by upping its stake in Redwood

Aileen Ruff

Global Strategic Marketing Director, Biologics and Sterile Technologies at Catalent...

Kemwell Talks Expansion and Approvals in India and the US

Kemwell Talks Expansion and Approvals in India and the US

Christian Ahlmark

Director of Corporate Development , Kemwell Biopharma

AMRI Exec Discusses 'New Bar' in FDA Enforcement

Following the completion of remediation efforts to deal with an FDA warning letter, Chris...

Happy holidays from William Reed Business Media!

Happy holidays from William Reed Business Media!

The working year is almost done, time to pause from ‘the business’ and embrace...

Aesica says academic partnerships are key for CMOs

Aesica says academic partnerships are key for CMOs

Alan Raymond

Sales & Marketing Director, Aesica Pharmaceuticals

Wockhardt targets CMO space for diversification

Wockhardt targets CMO space for diversification

Tom Salus

Associate Vice President, Business Development - Contract Services, Wockhardt

Kemwell and Boehringer set to finish biologics plant in India

Kemwell and Boehringer set to finish biologics plant in India

Christian Ahlmark

Director of corporate development , Kemwell